Cannabinoid Receptor 2 Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Cannabinoid Receptor 2 Agonists are pharmaceutical compounds that target and activate the CB2 receptors found primarily in the immune system and peripheral tissues. The mechanism of action involves binding to CB2 receptors, leading to the modulation of immune responses, inflammation, and pain perception. These agonists have shown potential in a range of disease indications, including rheumatoid arthritis, inflammatory bowel disease, neuroinflammatory disorders, chronic pain conditions, and autoimmune diseases. According to the World Health Organization (WHO), rheumatoid arthritis affects approximately 1% of the adult population in Europe and the United States, with higher prevalence rates in women. Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects over 3 million people in Europe, with increasing incidence rates reported in recent years. Neuroinflammatory disorders, such as multiple sclerosis, affect more than 700,000 individuals in Europe and approximately 1 million in the United States. Chronic pain conditions, including neuropathic pain and cancer-related pain, affect millions of people globally, with Europe and the United States experiencing a significant burden. Autoimmune diseases, such as lupus and psoriasis, collectively affect millions of individuals in Europe and the United States.

The growth of the Cannabinoid Receptor 2 Agonist market is driven by several factors. Firstly, the increasing research and understanding of the CB2 receptor and its role in various physiological processes have created opportunities for targeted therapeutics. Additionally, the growing body of evidence supporting the anti-inflammatory, analgesic, and neuroprotective properties of CB2 agonists fuels market demand. Companies such as Jazz, Corbus Pharma, GSK, Invion, Bionorica, Emerald Health Pharmaceuticals, Vertanical, Artelo Biosci, Pfizer, Centrexion Therap, Novartis, Insys Therap, and Eli Lilly. cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, GSK is currently conducting a clinical trial of the drug GW842166 for the treatment of acute myelocytic Arthritis.

Cannabinoid Receptor 2 Agonist Market Key Developments

• In May 2023, Benuvia Therapeutics pursued 505(b) fast-track approval with the US FDA for Investigational New Drugs for its dronabinol oral solution in Alzheimer's diesease
• In April 2022, GW Pharmaceuticals presented long-term efficacy and adverse events data from the phase III open-label extension GWPCARE6 trial Epidiolex in Tuberous sclerosis at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)

Approved Cannabinoid Receptor 2 Agonist molecules

• Dronabinol oral
• Epidiolex (cannabidiol)
• Syndros (dronabinol oral solution)

Cannabinoid Receptor 2 Agonist Pipeline Molecules

• Lenabasum (JBT-101)
• GW842166
• INV103
• Dronabinol (BX-1)
• EHP-101
• Dronabinol (VER-01)
• Olorinab (APD371)
• CNTX-6016
• CRA13
• LY2828360
• NTRX 07
• Cannabinor (PRS-211375)
• Tedalinab (GRC-10693)
• Vicasinabin (RG7774)

Clinical Activity and Development of Cannabinoid Receptor 2 Agonist

In the Cannabinoid Receptor 2 Agonist space, more than 10 companies are conducting more than 100 clinical trials in this category of drugs. For instance,

• In March 2022, Benuvia Therapeutics started Preclinical trials in Alzheimer's disease in the USA.
• In June 2023, Corbus Pharmaceuticals presented efficacy and adverse events data from a phase II trial of Resunab in systemic lupus erythematosus presented at the American College of Rheumatology and the Association of Rheumatology Professionals (ACR/ARP-2022)